View Cart (0 items)

Pfizer advocates experimental Alzheimer’s drug

February 15, 2012
/ Print / Reprints /
| Share More
/ Text Size+

NEW YORK — Speaking at an investor conference in New York on Tuesday, Pfizer Inc. research chief Mikael Dolsten said the company’s experimental treatment for Alzheimer''s disease is the drug industry''s "best chance" to delay progression of the illness, Reuters reported.

Dolsten said Pfizer''s drug, bapineuzumab, had far more complete and compelling data from already finished mid-stage clinical trials than Eli Lilly and Co''s solanezumab.

"This is so far the best chance the industry has for disease modification in Alzheimer''s," he said.

You must login or register in order to post a comment.